➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Litigation Details for Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Docket   Start Trial Date Filed 2012-03-21
Court District Court, D. Delaware Date Terminated 2014-12-08
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Patents 6,468,967; 6,852,689; 8,058,238; 8,129,342; RE39,071
Attorneys Derek James Fahnestock; Jack B. Blumenfeld; John C. Phillips , Jr.; Maryellen Noreika
Link to Docket External link to docket
Small Molecule Drugs cited in Cubist Pharmaceuticals Inc. v. Hospira Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-03-21 1 10. United States Patent No. 6,468,967 ("the '967 patent''), entitled "…CUBICm® prior to the expiration of U.S. Patent Nos. 6,468,967; 6,852,689; RE39,071; and 8,058,238 . … INFRINGEMENT OF U.S. PATENT NO. 6,468,967 18. Plaintiff incorporates… 1. This is an action for patent infringement under the patent laws of the United States, Title… 11. United States Patent No. 6,852,689 ("the '689 patent''), entitled " External link to document
2013-10-29 104 .D. Regarding the Validity of U.S. Patent Nos. RE39,071; 8,058,238; & 8,129,342 by Cubist Pharmaceuticals…2012 8 December 2014 1:12-cv-00367-GMS Patent None District Court, D. Delaware External link to document
2014-02-04 110 Exhibits 1-15, Part 3 claimed in U.S. Patents Nos. 6,468,967 (“the ’967 patent”) and 6,852,689 (“the ’689 patent”) has been approved…the ‘071 Patent, the ‘967 Patent, the ‘689 Patent, the ‘238 Patent, and/or the ‘342 Patents and the alleged…described in U.S. Patents Nos. 8,058,238 (“the ’238 patent”), and 8,129,342 (“the ’342 patent”) also contribute…the ’238 patent. The products disclosed and claimed in the ’238 patent and the ’342 patent—daptomycin…that U.S. Patent No. 4,537,717 inherently anticipates the ’071 patent, and that the ‘071 patent is an External link to document
2014-03-14 120 U.S. Patent 6,468,967 DTX 015 CUB00565500 CUB00565519 6/18/1985 U.S. Patent 4,524,135….S. Patent No. 6,468,967 PTX 002 CUBH000064 CUBH 000064-82 U.S. Patent No.…CUBH001432 File History for U.S. Patent 6,468,967 PTX 007 CUBH001433 CUBH001703…U.S. Patent 8,058,238 DTX 004 CUBH0008695 CUBH0008733 11/15/2011 U.S. Patent 8,058,238…U.S. Patent RE32,310 DTX 017 CUB00929529 CUB00929553 12/16/1986 U.S. Patent RE32, External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.